EP2709614A4 - Compositions pharmaceutiques et méthodes de traitement du cancer - Google Patents

Compositions pharmaceutiques et méthodes de traitement du cancer

Info

Publication number
EP2709614A4
EP2709614A4 EP12785724.1A EP12785724A EP2709614A4 EP 2709614 A4 EP2709614 A4 EP 2709614A4 EP 12785724 A EP12785724 A EP 12785724A EP 2709614 A4 EP2709614 A4 EP 2709614A4
Authority
EP
European Patent Office
Prior art keywords
methods
pharmaceutical compositions
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12785724.1A
Other languages
German (de)
English (en)
Other versions
EP2709614A1 (fr
Inventor
Oliver Rosen
Iain James Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of EP2709614A1 publication Critical patent/EP2709614A1/fr
Publication of EP2709614A4 publication Critical patent/EP2709614A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP12785724.1A 2011-05-17 2012-05-17 Compositions pharmaceutiques et méthodes de traitement du cancer Withdrawn EP2709614A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486851P 2011-05-17 2011-05-17
US201161538246P 2011-09-23 2011-09-23
PCT/US2012/038292 WO2012158884A1 (fr) 2011-05-17 2012-05-17 Compositions pharmaceutiques et méthodes de traitement du cancer

Publications (2)

Publication Number Publication Date
EP2709614A1 EP2709614A1 (fr) 2014-03-26
EP2709614A4 true EP2709614A4 (fr) 2015-04-15

Family

ID=47177338

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12785724.1A Withdrawn EP2709614A4 (fr) 2011-05-17 2012-05-17 Compositions pharmaceutiques et méthodes de traitement du cancer

Country Status (7)

Country Link
EP (1) EP2709614A4 (fr)
JP (1) JP2014513730A (fr)
AR (1) AR086444A1 (fr)
CA (1) CA2836277A1 (fr)
TW (1) TW201309291A (fr)
UY (1) UY34078A (fr)
WO (1) WO2012158884A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011218173C1 (en) 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
KR101926320B1 (ko) 2010-08-04 2018-12-06 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
UY33740A (es) * 2010-11-18 2012-05-31 Takeda Pharmaceutical Método para tratar el cáncer de mama y cáncer de ovarios
NZ744456A (en) * 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PL2945628T3 (pl) 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
CA2902335C (fr) * 2013-03-14 2021-09-14 Pellficure Pharmaceuticals, Inc. Nouvelle therapie pour le carcinome de la prostate
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20100261689A1 (en) * 2007-10-29 2010-10-14 Masuo Yamaoka Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
WO2007127010A2 (fr) * 2006-03-29 2007-11-08 The Regents Of The University Of California Composés de diarylthiohydantoïne

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20100261689A1 (en) * 2007-10-29 2010-10-14 Masuo Yamaoka Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012158884A1 *

Also Published As

Publication number Publication date
WO2012158884A1 (fr) 2012-11-22
CA2836277A1 (fr) 2012-11-22
JP2014513730A (ja) 2014-06-05
TW201309291A (zh) 2013-03-01
UY34078A (es) 2012-11-30
EP2709614A1 (fr) 2014-03-26
AR086444A1 (es) 2013-12-11

Similar Documents

Publication Publication Date Title
EP2755482A4 (fr) Compositions et méthodes de traitement du cancer
EP2890720A4 (fr) Compositions et méthodes de traitement du cancer
EP2836482A4 (fr) Compositions et méthodes pour le traitement du cancer
EP2709614A4 (fr) Compositions pharmaceutiques et méthodes de traitement du cancer
EP2552415A4 (fr) Méthodes de traitement du cancer
EP2760452A4 (fr) Méthodes de traitement du cancer
EP2736528A4 (fr) Compositions et méthodes de traitement du vih
EP2830661A4 (fr) Méthodes et compositions diagnostiques pour le traitement du cancer
EP2751570A4 (fr) Méthodes et compositions pour le traitement et le diagnostic du cancer
EP2740793A4 (fr) Composition de médicament pour traitement et/ou prévention du cancer
EP2740795A4 (fr) Composition de médicament pour traitement et/ou prévention du cancer
EP2740798A4 (fr) Composition de médicament pour traitement et/ou prévention du cancer
EP2670434A4 (fr) Traitement de tauopathies
EP2714081A4 (fr) Méthodes, compositions et trousses pour le traitement du cancer
EP2766043A4 (fr) Méthodes de traitement du syndrome de fuite vasculaire et du cancer
EP2847152A4 (fr) Compositions et méthodes de traitement du syndrome métabolique
EP2892546A4 (fr) Compositions et méthodes de traitement d'une cicatrice cutanée
EP2635286A4 (fr) Méthodes de traitement du cancer
EP2699256A4 (fr) Compositions et méthodes de traitement de maladie de devic
EP2920308A4 (fr) Traitement du cancer
EP2751561A4 (fr) Méthodes et compositions pour le traitement et le diagnostic du cancer colorectal
EP2635282A4 (fr) Compositions et méthodes de traitement de la myélofibrose
EP2723390A4 (fr) Arnsi de serpina1 : compositions et méthodes de traitement
EP2688594A4 (fr) Procédés et compositions pour le traitement du cancer
EP2776051A4 (fr) Associations thérapeutiques et méthodes de traitement du mélanome

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150317

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20150311BHEP

Ipc: A61K 31/4164 20060101ALI20150311BHEP

Ipc: A61K 31/40 20060101AFI20150311BHEP

Ipc: A61K 45/06 20060101ALI20150311BHEP

Ipc: A61K 31/00 20060101ALI20150311BHEP

Ipc: A61P 35/04 20060101ALI20150311BHEP

Ipc: A61K 31/4188 20060101ALI20150311BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151020